Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for α-1-antitrypsin deficiency

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 7, 2017, Pages 1655-1659

  Calcedo, Roberto ^a   Somanathan, Suryanarayan ^a   Qin, Qiuyue ^a   Betts, Michael R ^b   Rech, Andrew J ^a   Vonderheide, Robert H ^a   Mueller, Christian ^c   Flotte, Terence R ^c   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

A 1 antitrypsin; Adeno associated virus; Gene therapy; Immune response; Polymorphism

Indexed keywords

T LYMPHOCYTE RECEPTOR BETA CHAIN; ALPHA 1 ANTITRYPSIN; HLA ANTIGEN; PEPTIDE;

ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HAPLOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; T LYMPHOCYTE; TRANSGENE; ADULT; AGED; AMINO ACID SEQUENCE; CLINICAL TRIAL; DEPENDOPARVOVIRUS; FEMALE; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; K-562 CELL LINE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES;

ADULT; AGED; ALLELES; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; AMINO ACID SEQUENCE; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; HLA ANTIGENS; HUMANS; K562 CELLS; MALE; MIDDLE AGED; PEPTIDES; POLYMORPHISM, GENETIC; T-LYMPHOCYTES;

EID: 85013074473     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1617726114     Document Type: Article

References (27)

1. Maguire AM, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358(21):2240-2248.
2. Hauswirth WW, et al. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: Short-term results of a phase I trial. Hum Gene Ther 19(10):979-990.
3. Cideciyan AV, et al. (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105(39):15112-15117.
4. Eberling JL, et al. (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21):1980-1983.
5. Muramatsu S, et al. (2010) A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 18(9):1731-1735.
6. Nathwani AC, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365(25):2357-2365.
7. LeWitt PA, et al. (2011) AAV2-GAD gene therapy for advanced Parkinson's disease: A double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10(4):309-319.
8. Stroes ES, et al. (2008) Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28(12):2303-2304.
9. Mays LE, Wilson JM (2011) The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther 19(1):16-27.
10. Faust SM, et al. (2013) CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 123(7):2994-3001.
11. Gao G, et al. (2009) Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther 20(9):930-942.
12. Nathwani AC, et al. (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371(21):1994-2004.
13. Manno CS, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12(3):342-347.
14. Brantly ML, et al. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci USA 106(38):16363-16368.
15. Brantly ML, et al. (2006) Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 17(12):1177-1186.
16. Flotte TR, et al. (2004) Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 15(1):93-128.
17. Flotte TR, et al. (2011) Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: Interim results. Hum Gene Ther 22(10):1239-1247.
18. Mueller C, et al. (2013) Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 123(12):5310-5318.
19. Nielsen M, Lundegaard C, Lund O, Keşmir C (2005) The role of the proteasome in generating cytotoxic T-cell epitopes: Insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 57(1-2):33-41.
20. Nukiwa T, et al. (1986) Identification of a second mutation in the protein-coding sequence of the Z type alpha 1-antitrypsin gene. J Biol Chem 261(34):15989-15994.
21. Herson S, et al. (2012) A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 135(Pt 2):483-492.
22. Mendell JR, et al. (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68(5):629-638.
23. Hudrisier D, Mazarguil H, Laval F, Oldstone MB, Gairin JE (1996) Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications for peptide selection and presentation. J Biol Chem 271(30):17829-17836.
24. Mingozzi F, High KA (2013) Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood 122(1):23-36.
25. Calcedo R, et al. (2013) Self-reactive CFTR T cells in humans: Implications for gene therapy. Hum Gene Ther Clin Dev 24(3):108-115.
26. Takahashi H, Crystal RG (1990) Alpha 1-antitrypsin Null(isola di procida): An alpha 1-antitrypsin deficiency allele caused by deletion of all alpha 1-antitrypsin coding exons. Am J Hum Genet 47(3):403-413.
27. Kim Y, et al. (2012) Immune epitope database analysis resource. Nucleic Acid Res 40(Web Server issue):W525-530.